Trial Profile
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary)
- Indications Embolism and thrombosis
- Focus Adverse reactions
- Acronyms RE-FIT
- Sponsors Bristol-Myers Squibb
- 07 Aug 2018 Status changed from active, no longer recruiting to completed.
- 15 Feb 2018 Planned End Date changed from 31 Jan 2018 to 31 Jul 2018.
- 15 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 31 Jul 2018.